文献速递临床试验与 GCP

评估阿姆斯特林/谷胱甘肽病原体灭活红细胞在复杂心脏手术中的疗效与安全性:红细胞病原体灭活(ReCePI)研究——一项3期随机对照试验方案

Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
PubMed 文献 · Trials · 2023-12-11

ReCePI是一项前瞻性、多中心、随机、双盲、活性对照、平行设计、非劣效性3期临床试验,拟在心脏手术患者中比较病原体灭活红细胞(阿姆斯特林/谷胱甘肽处理)与常规去白细胞红细胞的安全性与有效性。主要有效性终点为术后48±4小时内发生急性肾损伤(血清肌酐较术前基线升高≥0.3 mg/dL或26.5 µmol/L)的输血患者比例,主要安全性终点为至28天与研究输血相关的不良事件及至末次输血后75天出现病原体灭活红细胞特异性抗体的比例。

要点

  • 心脏手术输血患者随机接受病原体灭活红细胞或常规去白细胞红细胞。
  • 主要有效性终点为术后48±4小时内急性肾损伤的发生比例。
  • ≥292例可评估输血患者(每组>146例)时,以80%把握度检验非劣效性。

核心结论

  • ReCePI研究旨在证明病原体灭活红细胞在支持急性贫血所致肾组织氧合方面不劣于常规红细胞,并描述治疗相关红细胞抗体的发生率。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、活性对照、平行设计、非劣效性3期临床试验。
  • 符合条件受试者在手术前最多7天随机分组,接受去白细胞试验组(病原体灭活)或对照组(常规)红细胞,输血时间自手术至术后第7天。
  • 可评估输血患者≥292例(每组>146例)时,研究具有80%把握度证明非劣效性;非劣效性定义为试验组急性肾损伤发生率较对照组升高不超过对照组发生率的50%,假设对照组发生率为30%。

主要发现

  • 主要有效性终点为至少接受一次研究输血且术后48±4小时内出现急性肾损伤诊断的患者比例,急性肾损伤定义为血清肌酐较术前基线升高≥0.3 mg/dL(或26.5 µmol/L)。
  • 主要安全性终点为至28天与研究红细胞输血相关的治疗中出现不良事件的患者比例,以及至末次研究输血后75天出现针对病原体灭活红细胞、特异性经确认的治疗中出现抗体的患者比例。

关键数值与推荐

  • 非劣效性界值:试验组急性肾损伤发生率升高不超过对照组发生率的50%。
  • 样本量假设:可评估输血患者≥292例(每组>146例),对照组急性肾损伤发生率假设为30%,把握度80%。
  • 急性肾损伤定义:血清肌酐较术前基线升高≥0.3 mg/dL(或26.5 µmol/L),发生于手术结束后48±4小时内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not performed and from residual donor leukocytes. Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leukocytes in RBC concentrates. The ReCePI study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of pathogen-reduced RBCs transfused for acute anemia in CVS compared to conventional RBCs, and to assess the clinical significance of treatment-emergent RBC antibodies. METHODS: ReCePI is a prospective, multicenter, randomized, double-blinded, active-controlled, parallel-design, non-inferiority study. Eligible subjects will be randomized up to 7 days before surgery to receive either leukoreduced Test (pathogen reduced) or Control (conventional) RBCs from surgery up to day 7 post-surgery. The primary efficacy endpoint is the proportion of patients transfused with at least one study transfusion with an acute kidney injury (AKI) diagnosis defined as any increased serum creatinine (sCr) level ≥ 0.3 mg/dL (or 26.5 µmol/L) from pre-surgery baseline within 48 ± 4 h of the end of surgery. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to pathogen-reduced RBCs through 75 days after the last study transfusion. With ≥ 292 evaluable, transfused patients (> 146 per arm), the study has 80% power to demonstrate non-inferiority, defined as a Test group AKI incidence increase of no more than 50% of the Control group rate, assuming a Control incidence of 30%. DISCUSSION: RBCs are transfused to prevent tissue hypoxia caused by surgery-induced bleeding and anemia. AKI is a sensitive indicator of renal hypoxia and a novel endpoint for assessing RBC efficacy. The ReCePI study is intended to demonstrate the non-inferiority of pathogen-reduced RBCs to conventional RBCs in the support of renal tissue oxygenation due to acute anemia and to characterize the incidence of treatment-related antibodies to RBCs.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Snyder EL, Sekela ME, Welsby IJ, et al. Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial. Trials. 2023. PMID: 38082326. doi:10.1186/s13063-023-07831-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。